Tiffany Alexander, MD
Obstetrics & Gynecology · Fort Smith, ARNPI 1164950499
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,000 of the $4,841 with a category attached, or 62.0%. Intuitive Surgical accounts for 94.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $4,646 and has fallen 96.4% since, to $166 in 2025.
Across 23 payments — averaging $210.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AbbVie$81
- Pfizer$37
- Hologic Sales And Service, LLC$25
- Astellas Pharma US Inc$24
- Biogen$21
- plus $88 from 5 others
What the payments were for
- Travel & lodging$1,56532%
- Food & beverage$2766%
- Education$3,00062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $4,565 |
| AbbVie | 5 | $81 |
| Pfizer | 2 | $37 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Biogen | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| BD | 1 | $17 |
| Exeltis, USA Inc. | 1 | $17 |
| Mylan Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$3,000
- Da Vinci Surgical System$1,527
How this compares
$4,841 in reported general payments places this provider in the 80th percentile of 272 obstetrics & gynecology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeozahFezolinetant | 12 | $6,642 |
| Estradiol | 22 | $1,218 |
| Fluconazole | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncVeozah | $24 | $6,64212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 272 obstetrics & gynecology providers in Arkansas.
Other obstetrics & gynecology in Fort Smith
- Jeanmarie HouseholderFort Smith$140K
- Timothy BellFort Smith$53K
- Thomas WoodFort Smith$12K
- Casey LawsFort Smith$11K
- Brock WilsonFort Smith$11K
- Kathleen StreetFort Smith$7K
- Andrew RicheFort Smith$5K
- Michael CopeLittle Rock$147K
- Paige PartridgeJohnson$50K
- David ShenkerLittle Rock$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.